Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma

Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma

Sphingolipid (SL) metabolism alterations have been frequently reported in cancer including in melanoma, a bad-prognosis skin cancer. In normal cells, de novo synthesized ceramide is mainly converted to sphingomyelin (SM), the most abundant SL, by sphingomyelin synthase 1 (SMS1) and, albeit to a less...

Full description

Bibliographic Details
Main Authors: Fatima Bilal, Anne Montfort, Julia Gilhodes, Virginie Garcia, Joëlle Riond, Stéphane Carpentier, Thomas Filleron, Céline Colacios, Thierry Levade, Ahmad Daher, Nicolas Meyer, Nathalie Andrieu-Abadie, Bruno Ségui
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-04-01
Series:Frontiers in Pharmacology
Subjects:
sphingolipids
ceramide
glucosylceramide
prognosis biomarker
cancer
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.00443/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2019.00443/full

Similar Items